|
|
 |
|
Viewing report
|
|
|
|
Endocrine Therapy for Breast Cancer
Informa Healthcare, July 2004, Pages: 350
Because of the predominant role estrogens play in the development of breast cancer and the limited effectiveness of tamoxifen therapy, more selective therapeutics targeting estrogen signaling have been developed: selective estrogen receptor modulators (SERMs), selective estrogen receptor downregulators (SERDs), and a third generation of drugs that inhibit the aromatase required for estrogen biosyntheses. The authors examine clinical and translational research results from studies of these endocrine therapies and chemotherapies in pre- and postmenopausal women with early and advanced breast cancer. Advances in Endocrine Therapy of Breast Cancer provides guidance on promising new therapeutics and treatment combinations based on compelling clinical evidence.
Customers who bought this item also bought
R&D Trends: Breast Cancer - Innovative approaches target key signaling pathways in breast tumors
Preclinical Cancer Therapeutics 2007: Decoding Next Generation Drug Targets for Market Success
Enabling Oncology Diagnostics: Predictive Biomarkers Based on Genes, Proteins, and Pathways
Molecular Diagnostics - Technologies, Markets and Companies
Cancer Therapeutics 2006: Market Dynamics and R&D Trends
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
Handbook of Metastatic Breast Cancer, Second Edition
Vitamin D. Edition No. 3
Nitric Oxide - Therapeutics, Markets and Companies
Vaccines in Clinical trials: Cancer
|
|
|
|
